Crossing the aortic valve can pose significant challenges, particularly in cases involving a horizontal aorta, bulky asymmetric calcifications, or prior prosthesis implantation in valve-in-valve procedures. While some TAVI devices feature deflectable delivery systems to enhance coaxiality, current self-expanding valves lack this capability. When standard techniques like...

Mirvat Alasnag provides her take on this clinical trial presented by Yundai Chen at the American College of Cardiology Scientific Session (ACC.23/WCC).

Alex Sticchi & Jonathan Curio provide their take on the clinical trial presented by Gregg W. Stone at the American College of Cardiology Scientific Sessions (ACC.23/WCC).

Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...

What’s the safest approach when surgical options are off the table? This real-life case shows how complex coronary revascularsation and TAVI were performed in a single session, supported by Impella.

Explore the rationale behind the sequence, the device choices, and the outcome in a high-risk patient with...

Nicola Ryan provides her take on the FULL REVASC trial which was presented at ACC.24 in Atlanta and published Simultaneously in NEJM.

The FULL REVASC trial is a multicentre registry-based randomised control trial comparing FFR-guided complete revascularisation of non-culprit lesions versus culprit lesion PCI alone in patients presenting...

Mirvat Alasnag provides her take on REC-CAGEFREE I, a multicenter, non-inferiority trial presented at the ESC Congress 2024 in London.

Analyze this EIJ image to see how surgical aortic bioprostheses with expandable ring technology can significantly enhance future ViV procedures.

Complex percutaneous coronary intervention (PCI) procedures are dramatically increasing in daily practice. Calcified coronary artery lesions and hostile cardiac anatomy may increase the risk of device dislodgment and/or malposition. In such situations, the use of a snare catheter is pivotal to retrieve and/or reposition the device.

REDUCE-AMI is a multicentre, registry-based, prospective open-label parallel-group randomised clinical trial evaluating the benefit of beta-blocker treatment in patients with acute MI and an ejection fraction >50% treated with a contemporary reperfusion strategy.

Nicola Ryan and Ali Nazmi Calik provide their take on the results which were presented...

Jonathan Curio and Alex Sticchi provide their take on this clinical trial which was presented by Paul Sorajja at the American College of Cardiology Scientific Session (ACC.23/WCC).

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Kalaivani Mahadevan and Fizzah Choudry provide their take on DAPT-SHOCK-MI presented by Zuzana Motovska at ESC Congress 2025 in Madrid.

The data from this study suggest that, from a SoMe perspective, correct Impella orientation is often overlooked, and that Impella malrotation is a common issue in real-world clinical practice, potentially associated with relevant complications.